Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 961243, 8 pages
Review Article

Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer

Department of Biology, Boston College, Chestnut Hill, MA 02467, USA

Received 17 December 2009; Revised 12 March 2010; Accepted 10 April 2010

Academic Editor: Arkadiusz Dudek

Copyright © 2010 Thomas N. Seyfried and Purna Mukherjee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Progression of malignant brain tumors is dependent upon vascularity and is associated with altered ganglioside composition and distribution. Evidence is reviewed showing that the simple monosialoganglioside, GM3, possesses powerful antiangiogenic action against the highly vascularized CT-2A mouse astrocytoma, which primarily expresses complex gangliosides. Brain tumors expressing high levels of GM3 are generally less vascularized and grow slower than tumors that express low levels of GM3. GM3 inhibits angiogenesis through autocrine and paracrine effects on vascular endothelial growth factor (VEGF) and associated receptors. GM3 should be a clinically useful compound for managing brain tumor angiogenesis.